Venous Thromboembolism Therapeutics Market 2017 Trend, Growth and Forecast to 2021
ReportsWeb.com published “Venous Thromboembolism Therapeutics Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this mark
(EMAILWIRE.COM, March 22, 2017 ) The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.
Publisher's analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.
For more information about this report: http://www.reportsweb.com/global-venous-thromboembolism-therapeutics-market-2017-2021 .
Covered in this report
The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Bayer HealthCare
- BMS
- Boehringer Ingelheim
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001685426/sample .
Other prominent vendors
- Altor Bioscience
- Armetheon
- Aspen Pharma
- BioInvent International
- eXIthera Pharmaceuticals
- Gamma Therapeutics
- GlycoMimetics
- Green Cross
- Isis Pharmaceutical
- Leo Pharma
- Pfizer
- Portola Pharmaceuticals
- ThromboGenics
Market driver
- Increasing surgical procedures such as hip and knee replacements.
- For a full, detailed list, view our report
Market challenge
- Presence of alternatives such as thrombectomy and percutaneous techniques.
- For a full, detailed list, view our report
Market trend
- Development of drugs for new indications.
- For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001685426/buying .
Publisher's analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.
For more information about this report: http://www.reportsweb.com/global-venous-thromboembolism-therapeutics-market-2017-2021 .
Covered in this report
The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Bayer HealthCare
- BMS
- Boehringer Ingelheim
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001685426/sample .
Other prominent vendors
- Altor Bioscience
- Armetheon
- Aspen Pharma
- BioInvent International
- eXIthera Pharmaceuticals
- Gamma Therapeutics
- GlycoMimetics
- Green Cross
- Isis Pharmaceutical
- Leo Pharma
- Pfizer
- Portola Pharmaceuticals
- ThromboGenics
Market driver
- Increasing surgical procedures such as hip and knee replacements.
- For a full, detailed list, view our report
Market challenge
- Presence of alternatives such as thrombectomy and percutaneous techniques.
- For a full, detailed list, view our report
Market trend
- Development of drugs for new indications.
- For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001685426/buying .
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results